Viking Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    529900IVC72YPFA25M37
    ISIN
    US92686J1060 (VKTX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    52 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€181.54M
    EBIT margin
    0.0%
    Net income
    -€146.32M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €6.12M +∞% -€308.03M +110.5%
    €8.96M +46.4% -€373.57M +21.3%
    €151.59M +1,592.6% -€345.31M -7.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 328K $7.91M +144K Buy

    Earnings Calls

    Latest earnings call: April 24, 2024 (Q1 2024)

    Add to watchlist

    Notifications